EVOGENE LTD (EVGN) Stock Price, Forecast & Analysis
USA - NASDAQ:EVGN - IL0011050551 - Common Stock
EVGN Key Statistics, Chart & Performance
The current stock price of EVGN is 1.18 USD. In the past month the price decreased by -4.76%. In the past year, price decreased by -25.93%.
EVGN Latest News, Press Relases and Analysis
EVGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.83 | 414.56B | ||
| AMGN | AMGEN INC | 15.63 | 183.99B | ||
| GILD | GILEAD SCIENCES INC | 15.39 | 156.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.1 | 111.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.86 | 75.64B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.29 | 60.99B | ||
| INSM | INSMED INC | N/A | 42.08B | ||
| NTRA | NATERA INC | N/A | 28.82B | ||
| BIIB | BIOGEN INC | 10.04 | 24.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 21.78B | ||
| INCY | INCYTE CORP | 16.36 | 20.51B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.33 | 13.82B |
Related stock screener links
About EVGN
Company Profile
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Company Info
EVOGENE LTD
13 Gad Feinstein Street, Park Rehovot
Rehovot 7414002 IL
CEO: Ofer Haviv
Employees: 117
Phone: 97289311900
EVOGENE LTD / EVGN FAQ
Can you describe the business of EVOGENE LTD?
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
What is the current price of EVGN stock?
The current stock price of EVGN is 1.18 USD. The price decreased by -1.67% in the last trading session.
Does EVOGENE LTD pay dividends?
EVGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of EVGN stock?
EVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists EVGN stock?
EVGN stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for EVGN stock?
EVOGENE LTD (EVGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.25).
Can you provide the upcoming earnings date for EVOGENE LTD?
EVOGENE LTD (EVGN) will report earnings on 2025-11-20, before the market open.
EVGN Technical Analysis
EVGN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EVGN. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative.
EVGN Financial Highlights
Over the last trailing twelve months EVGN reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 43.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EVGN Forecast & Estimates
7 analysts have analysed EVGN and the average price target is 2.55 USD. This implies a price increase of 116.1% is expected in the next year compared to the current price of 1.18.
For the next year, analysts expect an EPS growth of 29.49% and a revenue growth -56.03% for EVGN